Project
Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS ≥ 1.5)
Completed · 2013 until 2023
Silzle Tobias, Munz Jeannine, Quinter Janine
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2013
End Date
2023
Financing
SAKK
Labels
leukemia